title: Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
abstract: OBJECTIVE
  To assess the feasibility and morbidity of sequential cytoreductive surgery, carboplatin/paclitaxel chemotherapy, and consolidative abdominopelvic radiotherapy (APRT) in ovarian cancer.
  
  
  METHODS
  Between 1998 and 2000, 29 patients with optimally cytoreduced epithelial ovarian cancer were treated with carboplatin (135 mg/m2) and paclitaxel (area under the curve [AUC] of 6) followed by APRT in a prospective protocol. All patients were clinically, radiographically, and biochemically (CA-125) free of disease at the completion of chemotherapy. Abdominopelvic radiotherapy was delivered using 6 MV anterior-posterior photon fields to encompass the peritoneal cavity. Median follow-up was 4 years.
  
  
  RESULTS
  Two patients experienced Radiation Therapy Oncology Group Grade 3 gastrointestinal toxicity during APRT; 6 patients, Grade 3 or 4 neutropenia; and 3 patients, Grade 3 or 4 thrombocytopenia. Overall, 10 patients had Grade 3 or 4 acute toxicity. All of the acute side effects resolved after treatment was completed, and there were no serious consequences such as sepsis or hemorrhage. Abdominopelvic radiotherapy was abandoned prematurely in 3 patients. Late side effects were seen in 5 patients, including 1 small bowel obstruction, 2 symptomatic sacral insufficiency fractures, 1 case of severe dyspareunia, and 1 case of prolonged fatigue. All resolved with supportive management. The 4-year actuarial disease-free survival was 57%, and the overall survival was 92%. Eleven of 12 patients who relapsed received salvage chemotherapy, which was well tolerated.
  
  
  CONCLUSIONS
  Abdominopelvic radiotherapy after optimal surgery and carboplatin/paclitaxel chemotherapy is associated with an acceptable risk of acute and late side effects and does not limit subsequent salvage chemotherapy. Consolidative APRT warrants further investigation as a means of improving the outcome of patients with ovarian cancer.
authors.affiliation: Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Dinniwell
authors.forename: Michael
authors.initials: M
authors.lastname: Lock
authors.forename: Melania
authors.initials: M
authors.lastname: Pintilie
authors.forename: Anthony
authors.initials: A
authors.lastname: Fyles
authors.forename: Stephane
authors.initials: S
authors.lastname: Laframboise
authors.forename: Denny
authors.initials: D
authors.lastname: Depetrillo
authors.forename: Wilfred
authors.initials: W
authors.lastname: Levin
authors.forename: Lee
authors.initials: L
authors.lastname: Manchul
authors.forename: Joan
authors.initials: J
authors.lastname: Murphy
authors.forename: Amit
authors.initials: A
authors.lastname: Oza
authors.forename: Barry
authors.initials: B
authors.lastname: Rosen
authors.forename: Jeremy
authors.initials: J
authors.lastname: Sturgeon
authors.forename: Michael
authors.initials: M
authors.lastname: Milosevic
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel